Context Therapeutics (CNTX) Cash from Financing Activities (2020 - 2025)

Context Therapeutics has disclosed Cash from Financing Activities across 5 years of filings, most recently posting -$15268.0 for Q1 2025.

• Cash from Financing Activities for Q1 2025 came in at -$15268.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$15268.0 (down 100.01% YoY), and the FY2025 annual result was -$15268.0, down 100.01% from the prior year.
• Cash from Financing Activities came in at -$15268.0 for Q1 2025 at Context Therapeutics, down from $14.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $94.8 million in Q2 2024 to a low of -$816917.0 in Q3 2021.
• The 4-year median for Cash from Financing Activities is $1.9 million (2021), against an average of $18.6 million.
• Across the five-year window, Cash from Financing Activities surged 15393.75% in 2021 and tumbled 103.36% in 2022, its largest moves.
• Context Therapeutics' Cash from Financing Activities stood at $54.2 million in 2021, then plunged by 100.19% to -$102071.0 in 2022, then surged by 14340.09% to $14.5 million in 2024, then slumped by 100.11% to -$15268.0 in 2025.
• The last three Cash from Financing Activities figures came in at -$15268.0 (Q1 2025), $14.5 million (Q4 2024), and -$44632.0 (Q3 2024), per Business Quant data.